Cuyle Pieter-Jan, Prenen Hans
a Department of Gastroenterology/Digestive Oncology , Imelda General Hospital , Bonheiden , Belgium.
b Department of Gastroenterology/Digestive Oncology , University Hospitals Gasthuisberg Leuven , Leuven , Belgium.
Acta Clin Belg. 2017 Apr;72(2):103-115. doi: 10.1080/17843286.2016.1262996. Epub 2016 Dec 5.
Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. CRC develops as a consequence of genomic instability, characterized by various genetic and epigenetic alterations. Its molecular heterogeneity explains the large variability in patient prognosis and treatment response, emphasizing the need for development of accurate prognostic and predictive biomarkers. This article delineates the different pathways of colorectal carcinogenesis and its molecular subtype classification. With this review, we aim to provide a comprehensive overview of the current and future biomarkers guiding clinical decision-making and CRC treatment.
结直肠癌（CRC）是全球癌症死亡的主要原因之一。CRC是基因组不稳定的结果，其特征是各种基因和表观遗传改变。其分子异质性解释了患者预后和治疗反应的巨大差异，强调了开发准确的预后和预测生物标志物的必要性。本文阐述了结直肠癌发生的不同途径及其分子亚型分类。通过本综述，我们旨在全面概述指导临床决策和CRC治疗的当前及未来生物标志物。
